Introduction
In the early 1980s, there was considerable optimism that in vitro assays (e.g., the Ames test) would provide valuable insights into the potential for compounds to produce toxicity. Further 
Topics of Discussion

Definitions of Terms and Clarification of Concepts
In vitro teratology assays have a dual purpose, being used in both mechanistic and screening studies. The primary focus ofthe discussions at this conference was on the predictiveness of the assays for the outcome of Segment II teratology studies as required by regulatory agencies.
There was considerable discussion around the topic of semantics. There was no agreement, for example, on the definitions of prescreen, screen, and definitive studies. Some participants felt that Segment H animal studies, often referred to as teratology studies, are screens for potential adverse effects in humans and that any in vitro assay conducted in an initial assessment mode should be considered a prescreen. Others observed that effects in humans are difficult to determine, and Segment II data may be as definitive a set of developmental toxicity data as would be available; thus, an in vitro assay would be a screen for these effects. The term "prescreen" will be used here for any assay used to predict the outcome of Segment II studies. Participants 
Performance Characteristics of Prescreens
None ofthe prescreens were considered to be fully validated. Only the mouse ovarian tumor cell and human embryonic palatal mesenchymal cell assays have been evaluated in independent interlaboratory studies; thus, the level of concordance of prescreens with in vivo data cannot be assessed at this time. Metabolic activation has-not been uniformly achieved in the prescreens available at this time. In some cases the metabolic capabilities ofthe cells, organs, or organisms are not characterized. Whether a mammalian liver-derived 9000g supernatant (S-9) fraction or microsomes from cells that are known to have metabolic capability is the most appropriate source ofexogenous metabolic activity is a topic for further research. Would a metabolizing system be needed only for compounds showing no activity in assays?
The criteria for interpreting the results of prescreens are specific for each test, but there appear to be no universal criteria for interpreting the results of in vitro tests. The minimal study design needs to be established prior to any validation study. What will constitute a positive or negative effect? What is the confidence in a positive or (especially) negative outcome?
The end point concordance (defined as the ability to recapitulate in vivo data for either developmental toxicants or nondevelopmental toxicants) and the accuracy (defined as the overall ability to obtain the same outcome as in vivo tests) ofin vitro data for in vivo findings is uncertain; concordance may not necessarily be a requirement for a valid test (see "Validation"). Since concordance between Segment II results and effects in humans is variable depending on the species and test compounds, concordance is perhaps a moot point for prescreens.
The level of tolerance for false positives or false negatives was not agreed upon. The was no consensus about the minimum accuracy for a test to be useful. These levels may vary, depending on the purpose for which the assay is conducted.
Validation
Several speakers agreed that there is a general path to assay acceptability. In general, it is necessary to define the model and its significance (and limitations), characterize the test system, and conduct studies with a limited number of compounds. This is followed by an evaluation of the developed test, with intra-and interlaboratory standardization and testing with a larger number of coded compounds. Validated tests have broad acceptance, potential credibility for regulatory purposes, and have been used to test many agents. Studies to understand the scientific nature of the tests may be ongoing during any or all of these stages of validation.
Some prescreens have been developed to an extent where they warrant further validation. None of the prescreens was considered fully validated for broad prescreening purposes of compounds with unknown developmental toxicity. Some prescreens are sufficiently promising that they definitely warrant further validation efforts.
Development and refinement of systems for investigation of mechanisms of toxicity will take its own course. The exploration of systems for mechanistic research is independent of the validation considerations that would be imposed on tests used as prescreens.
There was no agreement reached about the criteria for and the approach to validation. If a prescreen is based on a highly specific mechanistic event, the fact that the event is measured in that test was considered to be sufficient validation by some investigators. Others considered that any prescreen must be able to properly distinguish between chemicals that are known to produce developmental toxicity and those that lack such properties and to distinguish selective embryotoxicity from general toxicity to be considered valid. Relevant concentrations and end points should be used.
It was generally agreed that testing protocols must be standardized to conduct validation studies. Further, it was suggested that investigators test compounds without knowledge of their identity and that outcomes be decided prior to decoding the data. The evaluation criteria must be clearly stated before the validation study is initiated. Interlaboratory concordance is essential; the assay must produce equivalent results in independent laboratories.
Future Efforts and Considerations
Consideration should be given to a validation approach of parallel testing with prescreens as chemicals are tested in Segment II studies. As organizations test specific chemicals in Segment II developmental toxicity screens, they should consider simultaneously testing the same substances in in vitro tests as prescreens to compare the outcome with that of Segment II studies. Publishing such comparisons would vastly expedite the evaluation of these tests, especially if industry-wide coordination was achieved.
Perhaps the most commonly agreed upon point of the whole workshop was the need for a new reference list of positive and negative agents as regards mammalian developmental toxicity. There was agreement that a new list was desirable; the chief criticism of the only published list (3), which has become the basis for preliminary validations, was that the assessment of maternal toxicity was not complete according to present day standards. It was pointed out that several known human teratogens act only at levels that produce obvious/overt maternal toxicity. Thus, excessive concern over maternal toxicity may not be warranted, as it is impossible at the present time to ascertain a causal relationship between maternal and developmental toxicity. Another criticism of that and other proposed lists is that there may be too many chemicals included that act by similar mechanisms. The primary purpose ofa new reference list would be to help focus further validation efforts and research to develop new test systems. Criteria must be established such that chemicals included on the list would permit a rigorous evaluation of any prescreen in subsequent validation studies. A variety ofcompounds should be considered for the list, representing gradations of developmental toxicity. Criteria for selection of chemicals for the reference list might include, but not necessarily be limited to: a) the weight of evidence for effects in animals and humans, b) the mechanism oftoxicity, chemical structure/function/class, c) the adult to developmental toxicity (A/D) ratio in developmental toxicity studies, and d) the selection ofchemicals that are structurally and configurationally closely related (e.g., enantiomers) known to be either positive or negative in in vivo screens.
Random selection from the universe of chemicals was not only considered unnecessary but probably inadvisable. Selection for and inclusion on the list must also take into account the cost and avilability of the chemicals as well as the ability to work safely with the substance in the laboratory.
An expert group should be asked to develop such a list, and consideration should be given to designating a subset of compounds that might be used as a short list to quickly evaluate the potential of a prescreen to produce results in concordance with the reference chemicals of established developmental toxicity. Concordance oftest outcome with the short list may then be used as a criterion to proceed with full-scale validation. There was a suggestion that human developmental toxicants may be useful as positive compounds on a short list. Graphical activity profiles for developmental toxicity end point described at the workshop (4) may be very useful in summarizing data for many compounds.
Experience from genetic toxicology validation studies designed to predict the outcome of carcinogenicity bioassays leads one to believe that adding additional assays (i.e., creating a battery of tests) may not improve predictive ability of short-term assays and may raise costs to unacceptable levels that are not competitive with conventional in vivo screening. Based on the experience in genetic toxicology, it is clear that validation studies must be well designed and managed. It what kind ofperformance (concordance) criteria are considered minimal performance for an assay. c) The role for in vitro teratology prescreening systems must be clearly defined (either for product development, regulatory use, or mechanistic studies). d) Too few in vitro teratology prescreens have been evaluated under multiple-laboratory trials with common, agreed-upon test agents to draw firm conclusions regarding the reproducibility of in vitro teratology prescreens. There is a need to move several of these assays further along the validation pathway, at least using a short list of reference compounds.
